Cabazitaxel (mCRPC, 2L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CABAZITAXEL DRUG-PREDNISONE |
|---|
| ID | REG-CABAZITAXEL-MCRPC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Used By
Drug
DRUG-CABAZITAXEL- Cabazitaxel
Handbook Chapters
HB-PROSTATE-MCRPC-1L- Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning
Indication
IND-PROSTATE-MCRPC-2L-CABAZITAXEL- IND-PROSTATE-MCRPC-2L-CABAZITAXEL
Regimen
REG-DOCETAXEL-MCRPC- Docetaxel (mCRPC)